These results also explain our previous study in the Cy/+IU rat model of progressive CKD-MBD where anti-sclerostin antibody increased trabecular bone volume/total volume (BV/TV) and trabecular mineralization surface in animals with low PTH, but not in animals with high PTH as SOST was already suppressed.38 The gene discussed is SOST; the disease is chronic kidney disease.